Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells
Alice Gutjahr, … , Stéphane Paul, Victor Appay
Alice Gutjahr, … , Stéphane Paul, Victor Appay
Published April 4, 2019
Citation Information: JCI Insight. 2019;4(7):e125107. https://doi.org/10.1172/jci.insight.125107.
View: Text | PDF
Research Article Vaccines

The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells

  • Text
  • PDF
Abstract

Pathogen recognition receptor (PRR) agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. Using an original in vitro approach to prime naive precursors from unfractionated human peripheral blood mononuclear cells, we assessed the influence of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), a ligand for the stimulator of interferon genes (STING), on the induction of antigen-specific CD8+ T cells. We found that 2′3′-cGAMP and 3′3′-cGAMP were especially potent adjuvants in this system, driving the expansion and maturation of functionally replete antigen-specific CD8+ T cells via the induction of type I IFNs. The biological relevance of these findings was confirmed in vivo using two mouse models, in which 2′3′-cGAMP–adjuvanted vaccination elicited protective antitumor or antiviral CD8+ T cell responses. These results identify particular isoforms of cGAMP as effective adjuvants that may find utility in the development of novel immunotherapies and vaccines.

Authors

Alice Gutjahr, Laura Papagno, Francesco Nicoli, Tomohiro Kanuma, Nozomi Kuse, Mariela Pires Cabral-Piccin, Nicolas Rochereau, Emma Gostick, Thierry Lioux, Eric Perouzel, David A. Price, Masafumi Takiguchi, Bernard Verrier, Takuya Yamamoto, Stéphane Paul, Victor Appay

×

Figure 4

STING ligands elicit a type I IFN response.

Options: View larger image (or click on image) Download as PowerPoint
STING ligands elicit a type I IFN response.
(A) Extracellular concentrat...
(A) Extracellular concentrations of various cytokines secreted by PBMCs in response to overnight stimulation with various PRR ligands. Each dot represents 1 donor per condition. Horizontal bars indicate median values. P values are represented as circles with variable size and color intensity (Mann-Whitney U test). (B) Frequency of EV10-specific CD8+ T cells and intracellular expression of T-bet, perforin, and granzyme B among EV10-specific CD8+ T cells primed in the presence of IFN-α (0.1 μg/ml), IFN-γ (0.1 μg/ml), or IL-12 (0.1 μg/ml). Each dot represents 1 HLA-A2+ donor per condition. Horizontal bars indicate median values. **P < 0.01, ***P < 0.001 (Kruskal-Wallis test). (C and D) Frequency of EV10-specific CD8+ T cells and intracellular expression of T-bet and granzyme B among EV10-specific CD8+ T cells primed in the presence of 2′3′-cGAMP, either alone or together with type I IFN blocking antibodies (C) or IL-10 (0.1 μg/ml) (D). *P < 0.05 (paired t test).

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts